Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Analyst consensus: Hold — five analysts cover Maravai (1 sell, 1 hold, 3 buy) with an average 12‑month price target of about $5.38.
• Recent quarter beat expectations (EPS of ($0.04) vs. ($0.07) and revenue $49.87M vs. $49.06M) but the company remains unprofitable with a large negative net margin (70.4%) and negative return on equity (22.79%).
• The stock trades around $3.68 with a market cap of roughly $946M, a negative P/E of -4.09, and a 52‑week range of $1.95–$4.11, while institutions own about 50.25% of shares.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) has been given a consensus recommendation of "Hold" by the five analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $5.3750.

Separately, Wall Street Zen raised shares of Maravai LifeSciences from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th.

Maravai LifeSciences Stock Performance

NASDAQ:MRVI opened at $3.68 on Friday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 5.69 and a current ratio of 6.60. The stock has a market capitalization of $946.02 million, a P/E ratio of -4.09 and a beta of 0.43. The company has a 50 day moving average price of $3.28 and a 200 day moving average price of $3.38. Maravai LifeSciences has a fifty-two week low of $1.95 and a fifty-two week high of $4.11.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 22.79%. The firm had revenue of $49.87 million during the quarter, compared to analysts' expectations of $49.06 million. Equities research analysts forecast that Maravai LifeSciences will post -0.26 EPS for the current year.

Hedge Funds Weigh In On Maravai LifeSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRVI. Sprott Inc. purchased a new position in Maravai LifeSciences in the 3rd quarter valued at approximately $29,000. Quantessence Capital LLC purchased a new position in Maravai LifeSciences in the 3rd quarter valued at approximately $31,000. Abel Hall LLC purchased a new stake in shares of Maravai LifeSciences during the 3rd quarter worth $33,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Maravai LifeSciences during the 3rd quarter worth $33,000. Finally, Virtu Financial LLC purchased a new stake in shares of Maravai LifeSciences during the 4th quarter worth $34,000. Hedge funds and other institutional investors own 50.25% of the company's stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.